Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Bought by Vontobel Holding Ltd.

Vontobel Holding Ltd. grew its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 28.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,000 shares of the company’s stock after acquiring an additional 4,000 shares during the period. Vontobel Holding Ltd.’s holdings in Allogene Therapeutics were worth $58,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ALLO. McGlone Suttner Wealth Management Inc. bought a new position in shares of Allogene Therapeutics during the fourth quarter worth about $27,000. EP Wealth Advisors LLC bought a new position in shares of Allogene Therapeutics during the third quarter worth about $34,000. Aaron Wealth Advisors LLC bought a new position in shares of Allogene Therapeutics during the fourth quarter worth about $34,000. Victory Capital Management Inc. bought a new position in shares of Allogene Therapeutics during the third quarter worth about $37,000. Finally, Dorsey & Whitney Trust CO LLC bought a new position in shares of Allogene Therapeutics during the third quarter worth about $39,000. Institutional investors own 83.63% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on ALLO shares. JMP Securities reaffirmed a “market perform” rating on shares of Allogene Therapeutics in a research report on Friday, January 5th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Tuesday, March 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Friday, March 15th. Guggenheim cut shares of Allogene Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, January 5th. Finally, JPMorgan Chase & Co. cut their target price on shares of Allogene Therapeutics from $9.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 27th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Allogene Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.94.

Allogene Therapeutics Trading Down 9.8 %

ALLO opened at $3.04 on Thursday. The business’s 50 day moving average is $4.44 and its 200-day moving average is $3.55. The stock has a market cap of $514.03 million, a PE ratio of -1.45 and a beta of 0.81. Allogene Therapeutics, Inc. has a twelve month low of $2.23 and a twelve month high of $6.89.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.04. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.05 million. Allogene Therapeutics had a negative return on equity of 53.76% and a negative net margin of 202,366.25%. As a group, analysts forecast that Allogene Therapeutics, Inc. will post -1.69 EPS for the current year.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).